Bristol Myers Q3 earnings: Cobenfy anxiety, PD-1xVEGF strategy and MFNnews2025-10-30T15:34:04+00:00October 30th, 2025|Endpoints News|
The showdown over Metsera: Pfizer and Novo prepare for a bidding warnews2025-10-30T15:20:13+00:00October 30th, 2025|Endpoints News|
Tectonic shares rise on back of Phase 1 heart failure datanews2025-10-30T15:18:52+00:00October 30th, 2025|Endpoints News|
Novo Nordisk’s new CEO is chasing the deals its former leaders wouldn’tnews2025-10-30T15:12:24+00:00October 30th, 2025|Endpoints News|
Evommune plans to raise about $150M in IPO for inflammatory diseasesnews2025-10-30T14:27:55+00:00October 30th, 2025|Endpoints News|
Boehringer licenses preclinical program from Kyowa Kirin; Savara makes a royalty dealnews2025-10-30T14:18:35+00:00October 30th, 2025|Endpoints News|
FDA puts two Intellia CRISPR trials on hold following liver toxicity casenews2025-10-30T13:45:08+00:00October 30th, 2025|Endpoints News|
Wave Life Sciences’ obesity biomarker data raise hopes for future readoutsnews2025-10-30T11:13:11+00:00October 30th, 2025|Endpoints News|
Takeda makes some pipeline cuts, says generic competition softened sales over last six monthsnews2025-10-30T11:09:35+00:00October 30th, 2025|Endpoints News|
